Keros Therapeutics (KROS) Other Non-Current Assets (2019 - 2025)

Keros Therapeutics' Other Non-Current Assets history runs 7 years deep, the most recent figure standing at $1.4 million for Q4 2025.

• Quarterly Other Non-Current Assets fell 3.38% year-over-year to $1.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.4 million (down 3.38% YoY) and the FY2025 annual result came in at $1.4 million, down 3.38% from the prior year.
• Other Non-Current Assets was $1.4 million for Q4 2025 at Keros Therapeutics, down from $1.4 million in the prior quarter.
• Across five years, Other Non-Current Assets topped out at $2.1 million in Q4 2023 and bottomed at $115000.0 in Q1 2021.
• A 5-year average of $1.3 million and a median of $1.3 million in 2021 frame the typical range for Other Non-Current Assets.
• Annual changes were most pronounced in 2021 — Other Non-Current Assets soared 1054.78% — and 2024, when it dropped 29.39%.
• Keros Therapeutics' Other Non-Current Assets stood at $1.3 million in 2021, then changed by 0.0% to $1.3 million in 2022, then jumped by 54.63% to $2.1 million in 2023, then fell by 29.39% to $1.4 million in 2024, then decreased by 3.38% to $1.4 million in 2025.
• Business Quant data shows KROS's Other Non-Current Assets at $1.4 million in Q4 2025, $1.4 million in Q3 2025, and $1.4 million in Q2 2025.